Utrecht

• Pro-RAPID Recruiting
  2023-507352-72-00 6 2024-05-24 Crohn's Disease
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• Safety, Tolerability, PK, PD, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia Recruiting
  2023-505995-31-00 7 2024-05-03 Glanzmann Thrombasthenia
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting
  2023-505602-42-00 4 2024-04-30 Spinal Muscular Atrophy (SMA)
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Small Lymphocytic Lymphoma
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate … Recruiting
  2023-505933-29-00 4 2024-03-13 IgM monoclonal gammopathy of unknown significance (MGUS) and myelin as
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f … Recruiting
  2024-510892-40-00 6 2024-02-29 Acute myocardial infarction complicated by cardiogenic shock
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting
  2023-507460-39-00 10 2024-02-15 Adult patients with resectable muscle-invasive urothelial cancer of th
• Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULC … Recruiting
  2022-502685-25-00 10 2024-01-01 The trial population will consist of patients with LAVC who require pr
• Mitapivat in Membranopathies Recruiting
  2023-503271-24-01 4 2023-12-29 erythrocyte membranopathies
• 24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting
  2022-502159-78-00 5 2023-12-06 Chronic Spontaneous Urticaria
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 7 2023-12-01 participants with isolated methylmalonic acidemia (MMA) due to methylm
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 4 2023-11-21 Low-grade serous ovarian cancer
• International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting
  2022-501869-41-00 9 2023-11-14 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 Relapsed/Refractory B-cell Malignancies
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting
  2022-503133-54-00 7 2023-08-09 Solid Tumors
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia

Showing 265–288 of 628 trials